ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 2 مورد

Zidovudine: Drug information

Zidovudine: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Zidovudine: Patient drug information" and "Zidovudine: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Hematologic toxicity:

Zidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease.

Myopathy:

Prolonged use of zidovudine has been associated with symptomatic myopathy.

Lactic acidosis/severe hepatomegaly:

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination, including with zidovudine and other antiretrovirals. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.

Brand Names: US
  • Retrovir
Brand Names: Canada
  • ALTI-Zidovudine;
  • APO-Zidovudine;
  • Retrovir (AZT)
Pharmacologic Category
  • Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)
Dosing: Adult

Note: Patients should receive IV therapy only until oral therapy can be administered.

Perinatal HIV-1 transmission, prevention

Perinatal HIV-1 transmission, prevention: Recommendations for use of intrapartum zidovudine are based on maternal HIV RNA levels assessed at 36 weeks' gestation or within 4 weeks of delivery, and other factors. Intrapartum zidovudine IV is recommended when HIV RNA is >1,000 copies/mL or when the HIV RNA level is unknown near delivery. Intrapartum zidovudine IV should also be administered if a lack of adherence is suspected since the last RNA result or when HIV is initially diagnosed during labor. Patients with HIV RNA >1,000 copies/mL should be given zidovudine even in cases of documented zidovudine resistance unless there is a history of hypersensitivity. Intrapartum zidovudine IV is not needed in patients receiving antiretroviral therapy (ART) who have HIV RNA <50 copies/mL near delivery AND who are adherent to their ART regimen. If a fetal scalp electrode is needed during labor, consider the fetal risk of HIV transmission high even if maternal HIV RNA is <50 copies/mL. The decision to administer zidovudine IV intrapartum to patients with HIV RNA ≥50 and ≤1,000 copies/mL near delivery should be made on a case-by-case basis (Ref).

During labor and delivery:

IV : Loading dose: 2 mg/kg over 1 hour followed by a continuous IV infusion of 1 mg/kg/hour until delivery (ie, clamping of the umbilical cord). For scheduled cesarean delivery, begin IV zidovudine at least 3 hours before surgery to provide dosing for a minimum of 3 hours. In cases of an urgent, unscheduled cesarean delivery due to maternal and fetal indications, consider administering the loading dose then proceeding to delivery (Ref). Note: Dosage based on total body weight.

HIV-1 infection, treatment

HIV-1 infection, treatment:

Note: Zidovudine is no longer recommended for use in treatment of HIV in the United States because of high rates of serious toxicities (Ref).

Oral: 300 mg twice daily, in combination with other antiretroviral agents.

IV: 1 mg/kg/dose every 4 hours around-the-clock (6 doses daily) in combination with other antiretroviral agents.

HIV-1 nonoccupational postexposure prophylaxis

HIV-1 nonoccupational postexposure prophylaxis (nPEP) (off-label use):

Note: Not a component of the recommended antiretroviral regimen for patients with CrCl ≥60 mL/minute (Ref).

Oral: 300 mg twice daily in combination with other antiretroviral agents. Initiate therapy within 72 hours of exposure and continue for 28 days (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

CrCl ≥15 mL/minute: No dosage adjustment necessary.

CrCl <15 mL/minute:

Oral: 100 mg every 6 to 8 hours.

IV: 1 mg/kg every 6 to 8 hours.

End-stage renal disease on intermittent hemodialysis:

Oral: 100 mg every 6 to 8 hours.

IV: 1 mg/kg every 6 to 8 hours.

Peritoneal dialysis:

Oral: 100 mg every 6 to 8 hours.

IV: 1 mg/kg every 6 to 8 hours.

CRRT: No adjustment needed (Ref).

Dosing: Liver Impairment: Adult

There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied). However, adjustment may be necessary due to extensive hepatic metabolism. Closely monitor patients for hematologic toxicities.

Dosing: Adjustment for Toxicity: Adult

Consider dose interruption for significant anemia (hemoglobin <7.5 g/dL or >25% reduction from baseline) and/or neutropenia (granulocyte count <750 cells/mm3 or >50% reduction from baseline) until evidence of recovery. Resumption in dose in combination with adjunctive measures (eg, epoetin alfa) may be appropriate, depending on erythropoietin level and patient tolerance.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Zidovudine: Pediatric drug information")

HIV-1 infection, treatment

HIV-1 infection, treatment: Use in combination with other antiretroviral (ARV) agents; evaluate gene mutation and ARV resistance patterns (refer to https://www.iasusa.org and https://hivdb.stanford.edu/ for more information). Although described in some international product labeling, IV zidovudine dosing is not recommended for treatment of HIV as other ARVs are only available as oral products, and administration of an incomplete regimen (zidovudine monotherapy) is not recommended. IV zidovudine dosing may still be utilized for prophylaxis in neonates or during labor/delivery; see "Dosing: Neonatal" or "Dosing: Adult" (Ref).

Infants (PMA ≥35 weeks, PNA ≥4 weeks, and weight ≥4 kg), Children, and Adolescents:

Weight-directed dosing:

4 to <9 kg: Oral: 12 mg/kg/dose twice daily.

9 to <30 kg: Oral: 9 mg/kg/dose twice daily.

≥30 kg: Oral: 300 mg twice daily.

BSA-directed dosing: Oral: 240 mg/m2/dose every 12 hours, range: 180 to 240 mg/m2/dose every 12 hours (maximum dose: 300 mg/dose).

HIV-1 nonoccupational postexposure prophylaxis

HIV-1 nonoccupational postexposure prophylaxis (nPEP) (Ref): Note: Initiate therapy within 72 hours of exposure and continue for 28 days; use in combination with other antiretroviral agents.

Infants (PMA ≥35 weeks and PNA ≥4 weeks of age) and Children:

4 to <9 kg: Oral: 12 mg/kg/dose twice daily.

9 to <30 kg: Oral: 9 mg/kg/dose twice daily.

≥30 kg: Oral: 300 mg twice daily.

Adolescents: Oral: 300 mg twice daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing adjustment for hematologic toxicity: Consider interruption of therapy for significant anemia (Hgb <7.5 g/dL or >25% decrease from baseline) and/or significant neutropenia (ANC <750 cells/mm3 or >50% decrease from baseline) until evidence of bone marrow recovery occurs; once bone marrow recovers, dose may be resumed using appropriate adjunctive therapy (eg, epoetin alfa); for persistent, severe anemia thought to be due to zidovudine, consider zidovudine discontinuation and implementation of a new regimen (Ref).

Dosing: Kidney Impairment: Pediatric

Infants >6 weeks, Children, and Adolescents:

The following adjustments have been recommended (Ref): Note: Renally adjusted dose recommendations are based on oral doses of 160 mg/m2/dose every 8 hours and IV dose of 120 mg/m2/dose every 6 hours.

GFR ≥10 mL/minute/1.73 m2: No dosage adjustment required

GFR <10 mL/minute/1.73 m2: Administer 50% of dose every 8 hours

Intermittent hemodialysis (IHD): Administer 50% of dose every 8 hours

Peritoneal dialysis (PD): Administer 50% of dose every 8 hours

Continuous renal replacement therapy (CRRT): No adjustment required

Dosing: Liver Impairment: Pediatric

There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied); however, dosage reduction may be necessary due to extensive hepatic metabolism. Use with caution; closely monitor for hematologic toxicities (Ref).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages noted with oral administration in adults unless otherwise indicated.

>10%:

Gastrointestinal: Anorexia (20%), nausea (51%), vomiting (17%)

Hematologic & oncologic: Anemia (neonates: 22%; adults: grades 3/4: 1%)

Nervous system: Headache (63%), malaise (53%)

1% to 10%:

Gastrointestinal: Abdominal cramps (≥5%), abdominal pain (≥5%), constipation (6%), dyspepsia (≥5%)

Nervous system: Asthenia (9%), chills (≥5%), fatigue (≥5%), insomnia (≥5%), neuropathy (≥5%)

Neuromuscular & skeletal: Arthralgia (≥5%), musculoskeletal pain (≥5%), myalgia (≥5%)

<1%: Hepatic: Hyperbilirubinemia

Frequency not defined:

Hematologic & oncologic: Neutropenia

Local: Injection-site reaction (IV, including irritation at injection site, pain at injection site)

Neuromuscular & skeletal: Lipoatrophy

Postmarketing (any population):

Cardiovascular: Cardiomyopathy, chest pain, orthostatic hypotension (Loke 1990), syncope, vasculitis

Dermatologic: Diaphoresis, dyschromia (including skin hyperpigmentation) (Premjith 2022), nail disease (changes in pigmentation including nail hyperpigmentation) (Chawre 2012, Premjith 2022), pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis (Murri 1996), urticaria

Endocrine & metabolic: Gynecomastia, increased lactate dehydrogenase, lactic acidosis (Mahto 2018), redistribution of body fat

Gastrointestinal: Dysgeusia, dysphagia, flatulence, oral mucosa hyperpigmentation, oral mucosa ulcer, pancreatitis (including acute pancreatitis) (Mahto 2018)

Genitourinary: Urinary frequency, urinary hesitancy

Hematologic & oncologic: Aplastic anemia, hemolytic anemia, leukopenia, lymphadenopathy, pancytopenia, pure red cell aplasia (Balakrishnan 2010)

Hepatic: Hepatitis, hepatomegaly with steatosis, jaundice

Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema)

Immunologic: Immune reconstitution syndrome

Nervous system: Anxiety, confusion, decreased mental acuity, depression, dizziness, drowsiness, mania, pain, paresthesia, seizure, tremor, vertigo

Neuromuscular & skeletal: Arthropathy (Murphy 1994), back pain, increased creatine phosphokinase in blood specimen, lipotrophy, muscle spasm, myopathy (Mahto 2018), myositis, rhabdomyolysis

Ophthalmic: Amblyopia, macular edema, photophobia

Otic: Hearing loss

Respiratory: Dyspnea, flu-like symptoms, rhinitis, sinusitis

Contraindications

Potentially life-threatening hypersensitivity to zidovudine or any component of the formulation

Canadian labeling: Additional contraindications (not in US labeling): Neutrophil count <750/mm3 or hemoglobin <7.5 g/dL (4.65 mmol/L)

Warnings/Precautions

Concerns related to adverse effects:

• Hematologic toxicity: Hematologic toxicity, including neutropenia and severe anemia have been reported with use, especially with advanced HIV-1 disease. Toxicity may be related to duration of use and prior bone marrow reserve. Hemoglobin reduction may occur in as early as 2 to 4 weeks; neutropenia usually occurs after 6 to 8 weeks. Pancytopenia has been reported (usually reversible). Use with caution in patients with bone marrow compromise (granulocytes <1,000 cells/mm3 or hemoglobin <9.5 g/dL). Dose interruption may be required in patients who develop anemia or neutropenia.

• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.

• Lipoatrophy: May cause loss of subcutaneous fat, especially in the face, limbs, and buttocks. Lipoatrophy incidence and severity are related to cumulative exposure and may be only partially reversible; improvement may take months to years after switching to a regimen that does not contain zidovudine. Monitor patients for signs of lipoatrophy and consider switching to a non-zidovudine-containing regimen if lipoatrophy occurs.

Disease-related concerns:

• Hepatic impairment: Hematologic toxicity may be increased due to increased serum concentrations in patients with hepatic impairment.

• Renal impairment: Use with caution in patients with CrCl <15 mL/minute; dosage adjustment recommended.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

Warnings: Additional Pediatric Considerations

Use with caution in patients with ANC <1,000 cells/mm3 or Hgb <9.5 g/dL; consider interruption of therapy for significant anemia (Hgb <7.5 g/dL or reduction >25% of baseline; neonates: Hgb <7 g/dL or symptomatic) or neutropenia (ANC <750 cells/mm3 or reduction >50% from baseline; neonates: ANC <500 cells/mm3) (HHS [pediatric] 2023; manufacturer's labeling). If significant anemia or neutropenia occur during treatment of HIV, discontinue concomitant marrow-toxic medications if possible, and treat coexisting iron deficiency, opportunistic infections, and/or malignancies; persistent, severe anemia or neutropenia may require changing the antiretroviral regimen. If significant anemia occurs during therapy for perinatal HIV prophylaxis, consult with a pediatric HIV expert to determine if early discontinuation should be considered. Zidovudine-related adverse hematologic effects may be concentration-dependent and associated with increasing AUC (Fillekes 2014; HHS [pediatric] 2023).

Adverse cardiac effects have been associated with zidovudine therapy. A prospective study of 325 pediatric patients aged 7 to 16 years with perinatally acquired HIV evaluated associations between previous or current antiretroviral agents and cardiac echocardiogram measures. When comparing patients currently receiving zidovudine (n=107) with those who were not, zidovudine therapy was associated with increased end-systolic wall stress and slightly larger heart size. Longer duration of zidovudine use was associated with higher wall stress (Williams 2018). A descriptive study evaluated 643 individuals 1 to 25 years of age with perinatally acquired HIV to determine prevalence of early cardiac dysfunction and reported that left ventricular ejection fraction was negatively associated with history of zidovudine exposure. Implications for cardiac outcomes later in life (eg, cardiomyopathy) are unknown (McCrary 2020; Williams 2018).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Retrovir: 100 mg [contains soybean lecithin]

Generic: 100 mg

Solution, Intravenous [preservative free]:

Retrovir: 10 mg/mL (20 mL)

Syrup, Oral:

Retrovir: 50 mg/5 mL (240 mL) [contains sodium benzoate; strawberry flavor]

Generic: 50 mg/5 mL (240 mL)

Tablet, Oral:

Generic: 300 mg

Generic Equivalent Available: US

May be product dependent

Pricing: US

Capsules (Retrovir Oral)

100 mg (per each): $3.24

Capsules (Zidovudine Oral)

100 mg (per each): $2.02

Solution (Retrovir Intravenous)

10 mg/mL (per mL): $1.75

Syrup (Retrovir Oral)

50 mg/5 mL (per mL): $0.32

Tablets (Zidovudine Oral)

300 mg (per each): $6.02

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

Retrovir (AZT): 100 mg [DSC]

Generic: 100 mg

Solution, Intravenous:

Retrovir (AZT): 10 mg/mL (20 mL)

Syrup, Oral:

Retrovir (AZT): 10 mg/mL (240 mL) [contains sodium benzoate]

Administration: Adult

Oral: Administer without regard to meals.

IV: Avoid rapid infusion or bolus injection. Do not administer IM.

Infuse over 1 hour; in pregnant patients, infuse loading dose over 1 hour followed by continuous infusion.

Administration: Pediatric

Oral: May be administered without regard to meals; use calibrated measuring device to accurately measure oral liquid dose; for neonatal patients, graduations of 0.1 mL are necessary due to small dose volumes.

Parenteral: IV infusion: Administer over 1 hour; in neonates, dose may be infused over 30 minutes. Do not administer IM; do not administer IV push or by rapid infusion.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2024 [table 2]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2023; NIOSH 2024; USP-NF 2020).

Note: Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.

Use: Labeled Indications

HIV-1 infection, treatment: Treatment of HIV-1 infection in combination with other antiretroviral agents. Note: Zidovudine is no longer recommended for use in treatment of HIV in the United States because of high rates of serious toxicities (HHS [ARV adult] 2023).

Perinatal HIV-1 transmission, prevention: Prevention of mother to fetus HIV-1 transmission.

Use: Off-Label: Adult

HIV-1 nonoccupational postexposure prophylaxis (nPEP)

Medication Safety Issues
Sound-alike/look-alike issues:

Azidothymidine may be confused with azaTHIOprine, aztreonam

Retrovir may be confused with acyclovir, ritonavir

Other safety concerns:

AZT is an error-prone abbreviation (mistaken as azithromycin, azaTHIOprine, aztreonam)

Metabolism/Transport Effects

Substrate of CYP2A6 (Minor), CYP2C19 (Minor), CYP2C9 (Minor), CYP3A4 (Minor), OAT1/3; Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Acemetacin: May increase adverse/toxic effects of Zidovudine. Specifically, the risk for hematologic toxicity may be increased. Risk C: Monitor

Amodiaquine: Zidovudine may increase neutropenic effects of Amodiaquine. Management: Avoid coadministration of zidovudine-containing antiretroviral therapy with amodiaquine when possible. If combined, monitor closely for neutropenia. Risk D: Consider Therapy Modification

Antithyroid Agents: Myelosuppressive Agents may increase neutropenic effects of Antithyroid Agents. Risk C: Monitor

Atidarsagene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Atidarsagene Autotemcel. Risk X: Avoid

BCG (Intravesical): Myelosuppressive Agents may decrease therapeutic effects of BCG (Intravesical). Myelosuppressive Agents may increase adverse/toxic effects of BCG (Intravesical). Risk X: Avoid

Betibeglogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Betibeglogene Autotemcel. Risk X: Avoid

Chloramphenicol (Ophthalmic): May increase adverse/toxic effects of Myelosuppressive Agents. Risk C: Monitor

Chloramphenicol (Systemic): Myelosuppressive Agents may increase myelosuppressive effects of Chloramphenicol (Systemic). Risk X: Avoid

Cladribine: Agents that Undergo Intracellular Phosphorylation may decrease therapeutic effects of Cladribine. Risk X: Avoid

Clarithromycin: May increase myelosuppressive effects of Zidovudine. Clarithromycin may decrease serum concentration of Zidovudine. Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction. Risk D: Consider Therapy Modification

CloZAPine: Myelosuppressive Agents may increase adverse/toxic effects of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor

Deferiprone: Myelosuppressive Agents may increase neutropenic effects of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Risk D: Consider Therapy Modification

Dexketoprofen: May increase adverse/toxic effects of Zidovudine. Risk C: Monitor

DOXOrubicin (Conventional): May decrease therapeutic effects of Zidovudine. DOXOrubicin (Conventional) may increase adverse/toxic effects of Zidovudine. Management: Avoid concomitant use of doxorubicin and zidovudine due to the possibility of reduced zidovudine efficacy and increased myelosuppressive effects. Risk D: Consider Therapy Modification

DOXOrubicin (Liposomal): May decrease therapeutic effects of Zidovudine. DOXOrubicin (Liposomal) may increase adverse/toxic effects of Zidovudine. Management: Avoid concomitant use of doxorubicin and zidovudine. Reduced efficacy of zidovudine is possible based on in vitro data. Also, increased myelosuppressive effects are possible with combined administration. Risk D: Consider Therapy Modification

Elivaldogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Elivaldogene Autotemcel. Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished Risk X: Avoid

Fexinidazole: Myelosuppressive Agents may increase myelosuppressive effects of Fexinidazole. Risk X: Avoid

Ganciclovir-Valganciclovir: May increase adverse/toxic effects of Zidovudine. Specifically, hematologic toxicity may be enhanced. Risk C: Monitor

Interferons: May increase adverse/toxic effects of Zidovudine. Interferons may decrease metabolism of Zidovudine. Risk C: Monitor

Levomethadone: May increase serum concentration of Zidovudine. Risk C: Monitor

Linezolid: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Lopinavir: May decrease serum concentration of Zidovudine. Risk C: Monitor

Lovotibeglogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Lovotibeglogene Autotemcel. Risk X: Avoid

Methadone: May increase serum concentration of Zidovudine. Risk C: Monitor

Nelfinavir: May decrease serum concentration of Zidovudine. Risk C: Monitor

Nirmatrelvir and Ritonavir: May decrease serum concentration of Zidovudine. Risk C: Monitor

Olaparib: Myelosuppressive Agents may increase myelosuppressive effects of Olaparib. Risk C: Monitor

Orlistat: May decrease serum concentration of Antiretroviral Agents. Risk C: Monitor

Probenecid: May increase serum concentration of Zidovudine. Risk C: Monitor

Promazine: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Raltegravir: May increase myopathic (rhabdomyolysis) effects of Zidovudine. Risk C: Monitor

Ribavirin (Oral Inhalation): Zidovudine may increase adverse/toxic effects of Ribavirin (Oral Inhalation). Specifically, the risk/severity of anemia may be increased. Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors. Risk D: Consider Therapy Modification

Ribavirin (Systemic): Zidovudine may increase adverse/toxic effects of Ribavirin (Systemic). Specifically, the risk/severity of anemia may be increased. Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors. Risk D: Consider Therapy Modification

RifAMPin: May decrease serum concentration of Zidovudine. Risk C: Monitor

Ritonavir: May decrease serum concentration of Zidovudine. Risk C: Monitor

Ropeginterferon Alfa-2b: Myelosuppressive Agents may increase myelosuppressive effects of Ropeginterferon Alfa-2b. Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects. Risk D: Consider Therapy Modification

Stavudine: Zidovudine may decrease therapeutic effects of Stavudine. Risk X: Avoid

Tenoxicam: May increase adverse/toxic effects of Zidovudine. Risk C: Monitor

Tipranavir: May decrease serum concentration of Zidovudine. Risk C: Monitor

Trimethoprim: Zidovudine may increase neutropenic effects of Trimethoprim. Trimethoprim may increase serum concentration of Zidovudine. Risk C: Monitor

Valproic Acid and Derivatives: May increase serum concentration of Zidovudine. Risk C: Monitor

Reproductive Considerations

Contraception is not required to initiate or continue antiretroviral therapy.

Zidovudine is an alternative nucleoside reverse transcriptase inhibitor for patients with HIV who are not yet pregnant but are trying to conceive.

Maximum viral suppression sustained below the limits of detection prior to conception is recommended for all persons with HIV who are planning a pregnancy. Prior to pregnancy, select or make changes to a specific antiretroviral regimen as part of a shared decision-making process. In most cases, recommendations based on data obtained from cisgender women can be applied to transgender and gender diverse people assigned female sex at birth.

Health care providers caring for couples planning a pregnancy when one or both partners are diagnosed with HIV may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2024).

Pregnancy Considerations

Zidovudine has a high level of transfer across the human placenta; the placenta also metabolizes zidovudine to the active metabolite.

No increased risk of overall teratogenic effects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may be associated with adverse pregnancy outcomes including preterm birth, low birth weight, and small for GA infants. High viral loads are also associated with adverse outcomes, including preterm birth and pregnancy loss. Treatment improves the health of the pregnant patient and reduces the risk of perinatal transmission. Do not withhold appropriate maternal ART due to concerns for adverse neonatal outcomes. Closely monitor for pregnancy complications. Document in utero ART exposure in the long-term medical record of a child born without HIV; evaluate for potential metabolic dysfunction if significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) develop.

Zidovudine is an alternative nucleoside reverse transcriptase inhibitor for pregnant patients with HIV who are antiretroviral-naive, who have had ART therapy in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). Patients who become pregnant while taking zidovudine may continue if viral suppression is effective and the regimen is well tolerated.

The pharmacokinetics of zidovudine are not significantly altered in pregnancy and dose adjustment is not needed.

Intrapartum zidovudine use is based on maternal HIV RNA levels assessed at 36 weeks' gestation or within 4 weeks of delivery, and other factors. Intrapartum zidovudine IV is recommended when HIV RNA is >1,000 copies/mL or when the HIV RNA level is unknown near delivery. Intrapartum zidovudine IV should also be administered if a lack of adherence is suspected since the last RNA result or when HIV is initially diagnosed during labor. Give patients with HIV RNA >1,000 copies/mL zidovudine even in cases of documented zidovudine resistance unless there is a history of hypersensitivity. Intrapartum zidovudine IV is not needed in patients receiving ART who have HIV RNA <50 copies/mL within 4 weeks of delivery AND who are adherent to their ART regimen. If a fetal scalp electrode is needed during labor, consider the fetal risk of HIV transmission high even if maternal HIV RNA is <50 copies/mL. The decision to administer zidovudine IV intrapartum to patients with HIV RNA ≥50 and ≤1,000 copies/mL within 4 weeks of delivery should be made on a case-by-case basis, and consider consistency in maintaining an undetectable viral load in the third trimester, compliance with prenatal care, or concerns with adherence.

ART is recommended for all pregnant people with HIV to maximize their health, maintain the viral load below the limit of an ultrasensitive assay detection, and reduce the risk of perinatal transmission. Start ART prior to conception or as soon as possible during pregnancy. During pregnancy, select or make changes to a specific antiretroviral regimen as part of a shared decision-making process. Patients on fully suppressive regimens prior to pregnancy generally may continue the same regimen considering known pregnancy outcomes and pharmacokinetic data. Monitor pregnant patients more frequently than nonpregnant patients. ART initiated during pregnancy can be modified after delivery. In most cases, recommendations based on data obtained from cisgender women can be applied to transgender and gender diverse people assigned female sex at birth.

Data collection to monitor pregnancy and infant outcomes following exposure to ART is ongoing. Enroll all patients exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263).

Health care providers caring for pregnant patients with HIV infection and their infants may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2024).

Breastfeeding Considerations

Zidovudine is present in breast milk.

Concentrations of zidovudine in breast milk may be similar to those in the maternal serum. Zidovudine has not been detected in the serum of breastfeeding infants exposed only via breast milk.

Provide patient-centered evidence-based counseling for infant feeding options as early as possible in pregnancy.

• Using properly prepared formula or pasteurized banked donor milk eliminates the risk of postnatal HIV transmission via breastfeeding.

• Counsel patients on antiretroviral therapy (ART) who achieve and maintain a consistently undetectable plasma viral load during pregnancy and postnatally about feeding options, including breastfeeding, formula feeding, or banked donor milk. Maintaining maximum viral suppression decreases but does not eliminate the risk of HIV transmission via breast milk. Temporary discontinuation of breastfeeding and use of replacement feeding may be required if maternal viral load becomes detectable or if mastitis or bleeding nipples develop. Permanent discontinuation of breastfeeding is recommended if the maternal HIV RNA is ≥200 copies/mL.

• Formula feeding or banked donor milk is recommended for persons with HIV who are not on ART and/or do not have sustained viral suppression. Provide the infant presumptive ART throughout breastfeeding and for up to 6 weeks after the last exposure to breast milk if the breastfeeding parent does not have sustained viral suppression but breastfeeding is continued; conduct infant virologic diagnostic testing at specified intervals.

• When the HIV status at delivery is not known, breast milk may be expressed and stored until a negative test is available.

• Discontinue breastfeeding immediately if HIV infection is diagnosed after breastfeeding has been initiated.

• Evaluate and provide support for maternal conditions that would make adherence to postpartum ART difficult.

Information is available for counseling and managing patients with HIV who are considering breastfeeding (1-888-448-8765). In most cases, recommendations based on data obtained from cisgender women can be applied to transgender and gender diverse people assigned female sex at birth (HHS [perinatal] 2024).

Monitoring Parameters

CBC with differential (more frequent monitoring required in patients with poor bone marrow reserve); LFTs; serum creatinine; HIV viral load and CD4 count.

Mechanism of Action

Zidovudine is a thymidine analog which interferes with the HIV viral RNA-dependent DNA polymerase resulting in inhibition of viral replication; nucleoside reverse transcriptase inhibitor

Pharmacokinetics (Adult Data Unless Noted)

Note: In general, pharmacokinetic data for pediatric patients >3 months to 12 years of age are similar to data in adult patients.

Absorption: Oral: Well absorbed

Distribution: Significant penetration into the CSF

Vd: 1 to 2.2 L/kg

CSF/plasma ratio:

Infants 3 months to Children 12 years (n=38): Median: 0.68; Range: 0.03 to 3.25

Adults (n=39): Median: 0.6; Range: 0.04 to 2.62

Protein binding: 25% to 38%

Metabolism: Hepatic via glucuronidation to inactive metabolites, including GZDV; extensive first-pass effect

Bioavailability: Oral: Similar for tablets, capsules, and syrup

Neonates <14 days: 89%

Infants 14 days to 3 months: 61%

Infants 3 months to Children 12 years: 65%

Adults: 64% ± 10%

Half-life elimination: Terminal:

Premature neonate: 6.3 hours

Full-term neonates: 3.1 hours

Infants 14 days to 3 months: 1.9 hours

Infants 3 months to Children 12 years: 1.5 hours

Adults: 0.5 to 3 hours (mean 1.1 hours)

Time to peak, serum: 30 to 90 minutes

Excretion:

Oral: Urine (72% to 74% as metabolites, 14% to 18% as unchanged drug)

IV: Urine (45% to 60% as metabolites, 18% to 29% as unchanged drug)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Cl is decreased, resulting in an increased half-life and AUC of zidovudine and major metabolite GZDV.

Hepatic function impairment: Clearance is decreased and plasma concentrations are increased.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Retrovir;
  • (AR) Argentina: Azoazol | Azotine | Crisazet | Enper | Exovir | Retrovir | Zetrotax | Zidovudina dosa | Zidovudina Filaxis | Zidovudina lando;
  • (AT) Austria: Retrovir;
  • (AU) Australia: Retrovir;
  • (BE) Belgium: Retrovir;
  • (BG) Bulgaria: Retrovir;
  • (BR) Brazil: Farmanguinhos zidovudina | Lafepe zidovudina | Retrovir | Virozid | Zidovudina;
  • (CH) Switzerland: Retrovir azt;
  • (CI) Côte d'Ivoire: Apo Zidovudine | Zidohope;
  • (CL) Chile: Azaviral | Retrovir | Retrovir azt | Zidovudina;
  • (CN) China: Ai jian | Apo Zidovudine | Fei te | Ke du | Na xin de | Pu xi ding | Qi luo ke | Retrovir | Zorpex;
  • (CO) Colombia: Ciplazidovir | Retrovir | Retrovir azt | Zido h | Zidovudina | Zidovudina azt;
  • (CZ) Czech Republic: Azitidin | Retrovir;
  • (DE) Germany: Retrovir | Zidovudin Aurobindo;
  • (DO) Dominican Republic: Lornox;
  • (EC) Ecuador: Retrovir | Zidovudina | Zidovudina nifa;
  • (EE) Estonia: Retrovir;
  • (EG) Egypt: Retrovir;
  • (ES) Spain: Retrovir | Zidovudina altan | Zidovudina combino pharm | Zidovudina G.E.S.;
  • (ET) Ethiopia: Zido h;
  • (FI) Finland: Retrovir;
  • (FR) France: Retrovir;
  • (GB) United Kingdom: Retrovir;
  • (GR) Greece: Retrovir;
  • (GT) Guatemala: Dovuvinex;
  • (HK) Hong Kong: Retrovir | Vick-Zidovudine;
  • (HU) Hungary: Retrovir;
  • (ID) Indonesia: Adovi | Retrovir | Reviral;
  • (IE) Ireland: Retrovir;
  • (IL) Israel: Retrovir;
  • (IN) India: Retrovir | Viro Z | Zidine | Zido h | Zidohope | Zidomax | Zidovex | Zidovir | Zilion | Zydowin;
  • (IT) Italy: Retrovir;
  • (JP) Japan: Retrovir;
  • (KE) Kenya: Aviro z | Retrovir | Zido h | Zidocos | Zidovir;
  • (KR) Korea, Republic of: Azidomine | Daehan azt | Hawon zidobudine | Retrovir | Yuhan zidovudin;
  • (KW) Kuwait: Retrovir;
  • (LB) Lebanon: Retrovir | Zidovir;
  • (LT) Lithuania: Retrovir;
  • (LU) Luxembourg: Retrovir;
  • (LV) Latvia: Retrovir;
  • (MX) Mexico: Isadol | Retrovir | Retrovir azt | Timivudin | Zidic c | Zidovir | Zidovudina | Zidovudina protein;
  • (MY) Malaysia: Retrovir | Viro Z | Zidovex | Zidovir;
  • (NG) Nigeria: Zido h;
  • (NL) Netherlands: Retrovir;
  • (NO) Norway: Retrovir;
  • (NZ) New Zealand: Retrovir;
  • (PE) Peru: Retrocar | Retrovir | Zidovudina;
  • (PH) Philippines: Retrovir;
  • (PL) Poland: Azovir | Retrovir;
  • (PR) Puerto Rico: Retrovir;
  • (PT) Portugal: Retrovir | Zidovudina | Zidovudina Aurobindo;
  • (PY) Paraguay: Zetrotax | Zidovudina icu vita;
  • (QA) Qatar: Retrovir;
  • (RO) Romania: Retrovir;
  • (RU) Russian Federation: Azidotimidin | Azimitem | Retrovir | Thymazid | Viro Z | Zido h | Zidovirine | Zidovirine azt | Zidovudin | Zidovudine avexima | Zidovudine azt | Zidovudine Ferein;
  • (SA) Saudi Arabia: Apo Zidovudine | Retrovir;
  • (SE) Sweden: Retrovir;
  • (SG) Singapore: Apo Zidovudine | Retrovir;
  • (SI) Slovenia: Retrovir;
  • (SK) Slovakia: Retrovir;
  • (SR) Suriname: Zidovir;
  • (TH) Thailand: Antivir | Apo Zidovudine | Retrovir | T Za | T.o. vir | Zidis;
  • (TN) Tunisia: Retrovir;
  • (TR) Turkey: Retrovir;
  • (TW) Taiwan: Retrovir;
  • (TZ) Tanzania, United Republic of: Aviro z | Zido h;
  • (UA) Ukraine: Nardin | Retrovir | Zidovudinum;
  • (UY) Uruguay: Azt | AZT FU | Crisazet | Enper | Retrovir | Zidovudina | Zidovudina Filaxis;
  • (VE) Venezuela, Bolivarian Republic of: Retrovir;
  • (ZA) South Africa: Adco zidovudine | Aspen Zidovudine | Auro Zidovudine | Cipla zidovudine | Dizovin | Dozra | Pharma Q Zidovudin | Pharma q zidovudine | Retrovir | Sonke zidovudine | Vari Zidovudine | Zidaid | Zidomat | Zidovir;
  • (ZM) Zambia: Aspen Zidovudine | Aviro z | Retrovir | Zidine | Zido h | Zidovir;
  • (ZW) Zimbabwe: Adco zidovudine | Aviro z | Retrovir | Zido h | Zidomat
  1. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  2. APO-Zidovudine [product monograph]. Toronto, Ontario, Canada: Apotex Inc; November 2023.
  3. Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 82.
  4. Balakrishnan A, Valsalan R, Sheshadri S, Pandit VR, Medep V, Agrawal RK. Zidovudine-induced reversible pure red cell aplasia. Indian J Pharmacol. 2010;42(3):189-191. doi:10.4103/0253-7613.66845 [PubMed 20871773]
  5. Bendayan R, Georgis W, and Rafi-Tari S, “Interaction of 3′-Azido-3′-Deoxythymidine With the Organic Base Transporter in a Cultured Renal Epithelium,” Pharmacotherapy, 1995, 15(3):338-44. [PubMed 7667167]
  6. Carpenter CC, Fischel MA, Hammer SM, et al, “Antiretroviral Therapy for HIV Infection in 1997. Updated Recommendations of the International AIDS Society - USA Panel,” JAMA, 1997, 277(24):1962-9. [PubMed 9200638]
  7. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  8. Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services (HHS). Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. https://stacks.cdc.gov/view/cdc/38856. Published April 18, 2016. Accessed July 11, 2016.
  9. Chawre SM, Pore SM, Nandeshwar MB, Masood NM. Zidovudine-induced nail pigmentation in a 12-year-old boy. Indian J Pharmacol. 2012;44(6):801-802. doi:10.4103/0253-7613.103306 [PubMed 23248416]
  10. Collins JM, Unadkat JD. Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet. 1989;17(1):1-9. [PubMed 2663302]
  11. D'Silva M, Leibowitz D, Flaherty JP. Seizure associated with zidovudine. Lancet. 1995;346(8972):452. [PubMed 7623605]
  12. Fillekes Q, Kendall L, Kitaka S, et al. Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children. Pediatr Infect Dis J. 2014;33(5):495-498. doi:10.1097/INF.0000000000000143 [PubMed 24736440]
  13. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990;112(10):727-737. [PubMed 1970466]
  14. Gill PS, Harrington W, Kaplan MH, et al, “Treatment of Adult T-Cell Leukemia-Lymphoma With a Combination of Interferon Alfa and Zidovudine,” N Engl J Med, 1995, 332(26):1744-8. [PubMed 7760890]
  15. Gorman SE, Dela Cruz F, and Paloucek F, “Ketoconazole and Zidovudine Overdose,” Am J Emerg Med, 1995, 13(1):115-6. [PubMed 7832939]
  16. Hagler DN, Frame PT. Azidothymidine neurotoxicity. Lancet. 1986;2(8520):1392-1393. [PubMed 2878246]
  17. Hargreaves M, Fuller G, Costello C, Gazzard B. Zidovudine overdose. Lancet. 1988;27;2(8609):509. [PubMed 2900428]
  18. Hermine O, Bouscary D, Gessain A, et al, “Brief Report: Treatment of Adult T-Cell Leukemia-Lymphoma With Zidovudine and Interferon Alfa,” N Engl J Med, 1995, 332(26):1749-51. [PubMed 7760891]
  19. Hilts AE and Fish DN, “Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,” Am J Health Syst Pharm, 1998, 55:2528-33. [PubMed 9853641]
  20. Hodson L, Ovesen J, Couch J, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. Managing hazardous drug exposures: information for healthcare settings, 2023. https://doi.org/10.26616/NIOSHPUB2023130. Updated April 2023. Accessed December 27, 2024.
  21. Hoggard PG, Veal GJ, Wild MJ, et al, “Drug Interactions With Zidovudine Phosphorylation in vitro,” Antimicrob Agents Chemother, 1995, 39(6):1376-8. [PubMed 7574535]
  22. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  23. Ioannidis JP, Cappelleri JC, Lau J, et al, “Early or Deferred Zidovudine Therapy in HIV-Infected Patients Without an AIDS-Defining Illness,” Ann Intern Med, 1995, 122(11):856-66. [PubMed 7741372]
  24. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al, “A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection,” N Engl J Med, 1995, 333(7):408-13. [PubMed 7616989]
  25. Kuhar DT, Henderson DK, Struble KA, et al, "Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis," Infect Control Hosp Epidemiol, 2013, 34(9): 875-92. [PubMed 23917901]
  26. Loke RH, Murray-Lyon IM, Carter GD. Postural hypotension related to zidovudine in a patient infected with HIV. BMJ. 1990;300(6718):163-164. doi:10.1136/bmj.300.6718.163 [PubMed 2105796]
  27. Mahto SK, Gupta PK, Taneja RS, Singh A. Zidovudine-induced lactic acidosis with acute pancreatitis and myopathy: lethal and rare complications. Indian J Pharmacol. 2018;50(4):212-214. doi:10.4103/ijp.IJP_285_18 [PubMed 30505059]
  28. Marchbanks K, Dudley MN, Posner MR, et al, “Pharmacokinetics and Pharmacodynamics of High-Dose Zidovudine Administered as a Continuous Infusion in Patients With Cancer,” Pharmacotherapy, 1995, 15(4):451-7. [PubMed 7479197]
  29. McCrary AW, Nyandiko WM, Ellis AM, et al. Early cardiac dysfunction in children and young adults with perinatally acquired HIV. AIDS. 2020;34(4):539-548. doi:10.1097/QAD.0000000000002445 [PubMed 31794518]
  30. McLeod GX and Hammer SM, “Zidovudine: Five Years Later,” Ann Intern Med, 1992, 117(6):487-501. [PubMed 1503352]
  31. Morris DJ, “Adverse Effects and Drug Interactions of Clinical Importance With Antiviral Drugs,” Drug Saf, 1994, 10(4):281-91. [PubMed 8018300]
  32. Mueller BU, Jacobsen F, Butler KM, et al, “Combination Treatment With Azidothymidine and Granulocyte Colony-Stimulating Factor in Children With Human Immunodeficiency Virus Infection,” J Pediatr, 1992, 121(5 Pt 1):797-802. [PubMed 1279153]
  33. Murphy D, Lynch M, Mulcahy F. Zidovudine related arthropathy. BMJ. 1994;309(6947):97. doi:10.1136/bmj.309.6947.97 [PubMed 8038679]
  34. Murri R, Antinori A, Camilli G, Zannoni G, Patriarca G. Fatal toxic epidermolysis induced by zidovudine. Clin Infect Dis. 1996;23(3):640-641. doi:10.1093/clinids/23.3.640 [PubMed 8879796]
  35. Newell ML and Gibb DM, “A Risk-Benefit Assessment of Zidovudine in the Prevention of Perinatal HIV Transmission,” Drug Saf, 1995, 12(4):274-82. [PubMed 7646826]
  36. Ovesen JL, Sam­mons D, Connor TH, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of hazardous drugs in healthcare settings, 2024. https://doi.org/10.26616/NIOSHPUB2025103. Updated December 18, 2024. Accessed December 20, 2024.
  37. Premjith R, Karthikeyan K. Zidovudine induced hyperpigmentation. Indian Dermatol Online J. 2022;13(3):398-399. doi:10.4103/idoj.idoj_449_21 [PubMed 36226018]
  38. Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Last modified December 2013. Available at http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php. Accessed December 30, 2015.
  39. Rachlis A and Fanning MM, “Zidovudine Toxicity: Clinical Features and Management,” Drug Saf, 1993, 8(4):312-20. [PubMed 8481217]
  40. Refer to manufacturer's labeling.
  41. Retrovir (zidovudine) [prescribing information]. Durham, NC: ViiV Healthcare; November 2024.
  42. Retrovir (zidovudine) [product monograph]. Montreal, Quebec, Canada: ViiV Healthcare ULC; June 2023.
  43. Skowron G, Bozzette SA, Lim L, et al, “Alternating and Intermittent Regimens of Zidovudine and Dideoxycytidine in Patients With AIDS or AIDS-Related Complex,” Ann Intern Med, 1993, 118(5):321-30. [PubMed 8094279]
  44. Taburet AM, Naveau S, Zorza G, et al, “Pharmacokinetics of Zidovudine in Patients With Liver Cirrhosis,” Clin Pharmacol Ther, 1990, 47(6):731-9. [PubMed 2357867]
  45. United States Pharmacopeia. <800> Hazardous Drugs—Handling in Healthcare Settings. In: USP-NF. United States Pharmacopeia; July 1, 2020. Accessed January 16, 2025. doi:10.31003/USPNF_M7808_07_01
  46. US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new. Updated March 23, 2023. Accessed May 16, 2023.
  47. US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. https://aidsinfo.nih.gov/guidelines/html/2/pediatric-treatment-guidelines/0/. Updated April 2020. Accessed June 2, 2020.
  48. US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new. Updated April 11, 2023. Accessed April 24, 2023.
  49. US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new. Updated December 30, 2021. Accessed January 3, 2022.
  50. US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. https://clinicalinfo.hiv.gov/en/guidelines/perinatal. Updated December 19, 2024. Accessed December 30, 2024.
  51. US Department of Health and Human Services (HHS). Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016. Available at https://stacks.cdc.gov/view/cdc/38856
  52. Volberding PA, Lagakos SW, Grimes JM, et al, “A Comparison of Immediate With Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults With CD4 Cell Counts of 500 or More Per Cubic Millimeter. AIDS Clinical Trials Group,” N Engl J Med, 1995, 333(7):401-7. [PubMed 7616988]
  53. Volberding PA, Lagakos SW, Koch MA, et al, “Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection. A Controlled Trial in Persons With Fewer Than 500 CD4-Positive Cells Per Cubic Millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases,” N Engl J Med, 1990, 322(14):941-9. [PubMed 1969115]
  54. Williams PL, Correia K, Karalius B, et al. Cardiac status of perinatally HIV-infected children: assessing combination antiretroviral regimens in observational studies. AIDS. 2018;32(16):2337‐2346. [PubMed 30102660]
  55. Wyles DL and Gerber JG, “Antiretroviral Drug Pharmacokinetics in Hepatitis with Hepatic Dysfunction,” Clin Infect Dis, 2005, 40(1):174-81. [PubMed 15614709]
Topic 10053 Version 345.0